From the helm: Opthea Ltd (ASX:OPT) Chief Executive Officer, Fred Guerard

In this latest instalment of Bell Direct’s From the helm series, we kick off 2025 with an exciting deep dive into the healthcare sector. Host Bell Direct’s Market Analyst, Grady Wulff sits down with Opthea (ASX:OPT) CEO, Fred Guerard to discuss the company’s remarkable 168% share price surge over the past six months as it advances toward commercialising its novel retinal disease treatment, Sozinibercept. With an initial focus on wet age-related macular degeneration, Opthea is poised to disrupt the market with its innovative approach to vision care. In this video, Fred discusses: • (0:43): Opthea’s history and its mission in the healthcare space • (1:40): how Sozinibercept compares to existing therapies • (3:22): recent Phase 3 data and confidence in trial success • (6:22): commercialisation strategy and financial runway • (8:15): key milestones and future pipeline treatments. Note: This interview was filmed on 5 February 2025.